Thyroid Cancer Fusion Gene Detection Kit
Cat Number: THRNA-RT32
The Thyroid Cancer Fusion Gene Detection Kit is a PCR-based assay that detects RET/PTC1, RET/PTC3, and PAX8/PPARγ fusion genes, which are associated with thyroid cancer diagnosis, prognosis, and targeted therapy selection.
- 32 tests per kit
- 2-hour turnaround time
- Works with FFPE, fresh frozen and FNA samples
- 3 Reactions per sample
- For research use (RUO) in the U.S
- For in vitro diagnostic use (IVD) in the European Union
Chromosomal translocations involving RET/PTC1, RET/PTC3, and PAX8/PPARγ are key oncogenic drivers in thyroid cancer, playing a crucial role in tumor initiation and progression. These fusion genes are particularly associated with papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC), and their detection is essential for differentiating malignant thyroid tumors from benign nodules.
The Thyroid Cancer Fusion Gene Detection Kit is a real-time PCR-based assay designed for the sensitive and specific detection of RET/PTC1, RET/PTC3, and PAX8/PPARγ (PAX8 exon 7 and exon 9 variants) fusion genes. This assay integrates first-strand cDNA synthesis and simultaneous amplification of fusion and reference genes in a single-step reaction, streamlining the workflow and reducing processing time.
The kit is optimized for use with total RNA isolated from fine needle aspirates (FNA), fresh-frozen tissues, cell lines, and formalin-fixed paraffin-embedded (FFPE) samples.
The Thyroid Cancer Fusion Gene Detection Kit follows a simple and easy to use process. It can be completed in 2 hours and follows a simple straightforward process.
EntroGenʼs Thyroid Fusion Gene Detection Kit requires a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes. This test includes reagents required for PCR amplification/detection, as well as validated reaction controls.
Columns and reagents for RNA isolation are not included.
Click to download lot-specific quality control data for your product:
